743. Variability of Resistance Rates among Streptococcus spp. Isolated from Different Regions and Sources of Infection (TEST 2008-2012)
Session: Poster Abstract Session: Antimicrobials: Resistance Mechanisms
Friday, October 4, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • IDSA 743.pdf (608.7 kB)
  • Background: Streptococcus pneumoniae (SPN) and S. agalactiae (BSB) can cause serious infections, particularly among neonates, the elderly and patients that are immunocompromised. These species are associated with various infections in several anatomic organ systems, including reproductive (REP), genitourinary (GU), bone and joint (BJ), respiratory (RES), bloodstream (BS), skin and skin structure (SSSI), ear-nose-throat (ENT) and central nervous system (CNS). This study documents the susceptibility (S) rates observed for several antimicrobial agents tested over a five year surveillance study (TEST) comparing susceptibility (S)% for each source of infection.

    Methods: Isolates were collected from multiple countries in 7 geographic regions and tested locally by broth microdilution using CLSI guidelines and S% is reported using CLSI and FDA breakpoints for tigecycline (TIG). S and resistance (R) rates were analyzed for tigecycline (TIG) and appropriate comparator agents for SPN and BSB in these regions.

    Results: Table:á Selected S rates for SPN by region for three agents tested.

    TIG and vancomycin showed 100 and >99.9% S against BSB and SPN, respectively. Penicillin (PEN)-R was lowest among REP (8.3%), BS (29.5%), GU (31.6%) and CNS (33.8%) compared to SSSI, RES and ENT (38.7-42%) and co-R to erythromycin (ER) and clindamycin (CL) was highest among these three sources. 1-2% of these streptococci were non-S to levofloxacin.

    Conclusion: Regional variation was observed for PEN, ER and CL, generally higher in Asia and Africa. This data also shows S differences based upon the source of infection for some tested agents with higher R rates observed among RES, ENT and SSSI isolates. TIG had activity against nearly 100% of the strains regardless of infection source.

     

    Douglas Biedenbach, BS1, Stephen Hawser, PhD2, Meredith Hackel, PhD3, Samuel Bouchillon, MD3, Daryl Hoban, PhD3, Robert Badal, BS4 and Heidi Leister-Tebbe, BS5, (1)International Health Management Associates, Inc., Schaumburg, IL, (2)IHMA Europe SÓrl, Epalinges, Switzerland, (3)Ihma, Inc., Schaumburg, IL, (4)IHMA, Inc., Schaumburg, IL, (5)Pfizer Inc., Collegeville, PA

    Disclosures:

    D. Biedenbach, None

    S. Hawser, None

    M. Hackel, None

    S. Bouchillon, None

    D. Hoban, None

    R. Badal, None

    H. Leister-Tebbe, Pfizer Inc.: Employee, Salary

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.